SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Gwen Ifill Synthetic CCD

PatientGwen Ifill
Date of birth1965-09-29
IdentifiersMRN HR-ML032-SYN; SSN (made up) 000-32-5814
Document date2026-11-01
AuthorLorna Achebe-Price, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Three weeks of postmenopausal bleeding in a woman of 60: examination, office endometrial biopsy, transvaginal ultrasound, and gynecologic oncology review booked. Concerns: Spotting, then light bleeding on and off for about three weeks, eight years after her periods stopped; no pain; She does not want a wait-and-see answer: she knows that bleeding after menopause is sometimes put down to nothing, and she wants the cause found quickly and told plainly; She wants to keep working and to decide who is told. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-02-03 to 2026-02-17completedS
Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2026-02-24 to 2026-06-09completedS
Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2026-02-24 to 2026-06-09completedS
Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidineDay 1 every 21 days for six cyclesIntravenous route2026-02-24 to 2026-06-09completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as needed for nauseaOral route2026-02-24 to 2026-06-30completedS
Dostarlimab 50 mg/mL injection, 1000 mg intravenously over 30 minutes every 6 weeks as maintenance, for up to three yearsEvery 6 weeksIntravenous route2026-06-30activeS
Levothyroxine 75 mcg oral tablet, one tablet daily before breakfastOne tablet daily before breakfastOral route2026-06-30activeS

Procedures

ProcedureDatesStatusEvidence
Office endometrial biopsy with a suction catheter (Pipelle), with a chaperone, after verbal consent: adequate tissue obtained; tolerated with mild cramping2026-01-05 to 2026-01-05completedS
Transvaginal ultrasound of the pelvis: endometrium 16 mm, heterogeneous, with an irregular junction with the myometrium and internal blood flow; two small intramural fibroids (1.8 cm and 1.2 cm); ovaries normal for age; no free fluid2026-01-07 to 2026-01-07completedS
CT of the chest, abdomen and pelvis with contrast: enlarged, heterogeneous uterine cavity; a 1.5 cm right external iliac lymph node and a 1.7 cm left para-aortic lymph node below the renal veins, both suspicious; no liver, lung, bone or peritoneal lesion; no ascites2026-01-13 to 2026-01-13completedS
Advance care planning conversation, about 20 minutes2026-08-11 to 2026-08-11completedS
Screening mammogram, both breasts2026-08-25 to 2026-08-25completedS
Robotic-assisted total laparoscopic hysterectomy with removal of both fallopian tubes and ovaries and pelvic washings. Pathology: endometrioid adenocarcinoma, FIGO grade 2 (low grade), 4.2 cm, invading 65% of the myometrial thickness; no cervical stromal invasion; focal (not substantial) lymphovascular space invasion; tubes, ovaries and serosa free; washings negative. Mismatch repair deficient (loss of MLH1 and PMS2), MLH1 promoter hypermethylated, POLE wild-type, p53 wild-type; estrogen receptor positive. FIGO 2023 stage IIIC2ii, molecular class MMRd2026-02-03 to 2026-02-03completedS
Sentinel lymph node mapping with indocyanine green, both sides of the pelvis: right external iliac sentinel node with a 9 mm metastasis; left obturator sentinel node negative on ultrastaging2026-02-03 to 2026-02-03completedS
Excision of the enlarged left para-aortic lymph node seen on CT, with adjacent para-aortic nodes below the renal veins: 1 of 4 nodes involved (14 mm deposit)2026-02-03 to 2026-02-03completedS
Genetic counseling: universal Lynch syndrome tumor screening explained; MLH1 and PMS2 loss explained by MLH1 promoter hypermethylation, which is acquired in the tumor and not inherited; germline testing not indicated; she was told what would change that advice2026-02-24 to 2026-02-24completedS
CT of the chest, abdomen and pelvis with contrast at the end of combination treatment: no enlarged pelvic or para-aortic lymph node, no vaginal cuff mass, no liver, lung, bone or peritoneal lesion; expected postoperative changes (no evidence of disease)2026-06-23 to 2026-06-23completedS

Immunizations

DateVaccineStatusEvidence
2026-08-11Pneumococcal conjugate vaccine PCV20completedS
2026-08-11Recombinant zoster vaccine, dose 1 of 2completedS
2026-08-11Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

No historical medical events are recorded.

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Spotting, then light bleeding on and off for about three weeks, eight years after her periods stopped; no painactiveS
She does not want a wait-and-see answer: she knows that bleeding after menopause is sometimes put down to nothing, and she wants the cause found quickly and told plainlyactiveS
She wants to keep working and to decide who is toldactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 11.4 on 2026-06-30; Leukocytes [#/volume] in Blood by Automated count 4.9 on 2026-06-30; Platelets [#/volume] in Blood by Automated count 228 on 2026-06-30; Creatinine [Mass/volume] in Serum or Plasma 0.84 on 2026-06-30; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 80 on 2026-06-30; Glucose [Mass/volume] in Serum or Plasma 93 on 2026-08-11; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2026-01-05; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-08-11; Neutrophils [#/volume] in Blood by Automated count 2.8 on 2026-06-30; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-01-20; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-01-20; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 2026-08-11; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-06-30; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 2026-06-30; Albumin [Mass/volume] in Serum or Plasma 4 on 2026-02-24; Cancer Ag 125 [Units/volume] in Serum or Plasma 28 on 2026-01-20; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-06-30; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 7 on 2026-01-20; Magnesium [Mass/volume] in Serum or Plasma 1.8 on 2026-04-28; Thyrotropin [Units/volume] in Serum or Plasma 3.6 on 2026-08-11; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 on 2026-08-11; Cortisol [Mass/volume] in Serum or Plasma 13.1 on 2026-06-30; Cholesterol [Mass/volume] in Serum or Plasma 204 on 2026-08-11; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 124 on 2026-08-11; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 2026-08-11; Triglyceride [Mass/volume] in Serum or Plasma 110 on 2026-08-11 [S]

Strengths and supports: Lives alone in Washington, D.C.; has no children. Supports: a large extended family she is close to, many friends, and her church community [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review bookedresolvedconfirmed N95.0S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation.
Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial canceractiveconfirmed C54.1S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public.
Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2023 stage IIIC2iiactiveconfirmed C77.8S — Synthetic nodal disease found at surgical staging.
Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes, grade 1 (sensory only, no effect on daily activities)activeconfirmed G62.0S — Synthetic common effect of paclitaxel.
Immune-related primary hypothyroidism from dostarlimab: TSH 11.8 with a low free T4, tiredness and feeling cold (grade 2)activeconfirmed E03.2S — Synthetic immune-related adverse event, among the most common with PD-1 inhibitors.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-05Hemoglobin [Mass/volume] in Blood11.8g/dL12-15.5 g/dLLowS
2026-01-05Leukocytes [#/volume] in Blood by Automated count6.210*3/uL4-11 10*3/uLNormalS
2026-01-05Platelets [#/volume] in Blood by Automated count26810*3/uL150-400 10*3/uLNormalS
2026-01-05Creatinine [Mass/volume] in Serum or Plasma0.82mg/dL0.59-1.04 mg/dLNormalS
2026-01-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M82mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-01-05Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-01-05Hemoglobin A1c/Hemoglobin.total in Blood5.5%Below 5.7% is normal; 5.7 to 6.4% prediabetesNormalS
2026-01-05Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-01-20Hemoglobin [Mass/volume] in Blood12.1g/dL12-15.5 g/dLNormalS
2026-01-20Leukocytes [#/volume] in Blood by Automated count610*3/uL4-11 10*3/uLNormalS
2026-01-20Neutrophils [#/volume] in Blood by Automated count3.610*3/uL1.5-7.7 10*3/uLNormalS
2026-01-20Platelets [#/volume] in Blood by Automated count27410*3/uL150-400 10*3/uLNormalS
2026-01-20Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-01-20Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-01-20Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
2026-01-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-01-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-35 U/LNormalS
2026-01-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L8-35 U/LNormalS
2026-01-20Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-01-20Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-01-20Cancer Ag 125 [Units/volume] in Serum or Plasma28U/mL<=35 U/mLNormalS
2026-01-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-01-20Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S
2026-02-24Hemoglobin [Mass/volume] in Blood11.6g/dL12-15.5 g/dLLowS
2026-02-24Leukocytes [#/volume] in Blood by Automated count6.410*3/uL4-11 10*3/uLNormalS
2026-02-24Neutrophils [#/volume] in Blood by Automated count3.910*3/uL1.5-7.7 10*3/uLNormalS
2026-02-24Platelets [#/volume] in Blood by Automated count30110*3/uL150-400 10*3/uLNormalS
2026-02-24Creatinine [Mass/volume] in Serum or Plasma0.78mg/dL0.59-1.04 mg/dLNormalS
2026-02-24Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M87mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-02-24Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
2026-02-24Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
2026-02-24Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L8-35 U/LNormalS
2026-02-24Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL0.1-1.2 mg/dLNormalS
2026-02-24Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-02-24Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.7-2.2 mg/dLNormalS
2026-02-24Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4.5 mIU/LNormalS
2026-02-24Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
2026-02-24Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-04-28Hemoglobin [Mass/volume] in Blood10.6g/dL12-15.5 g/dLLowS
2026-04-28Leukocytes [#/volume] in Blood by Automated count4.310*3/uL4-11 10*3/uLNormalS
2026-04-28Neutrophils [#/volume] in Blood by Automated count2.110*3/uL1.5-7.7 10*3/uLNormalS
2026-04-28Platelets [#/volume] in Blood by Automated count19610*3/uL150-400 10*3/uLNormalS
2026-04-28Creatinine [Mass/volume] in Serum or Plasma0.81mg/dL0.59-1.04 mg/dLNormalS
2026-04-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M83mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-28Glucose [Mass/volume] in Serum or Plasma97mg/dL70-99 mg/dLNormalS
2026-04-28Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
2026-04-28Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L8-35 U/LNormalS
2026-04-28Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-04-28Magnesium [Mass/volume] in Serum or Plasma1.8mg/dL1.7-2.2 mg/dLNormalS
2026-04-28Thyrotropin [Units/volume] in Serum or Plasma4.8m[IU]/L0.4-4.5 mIU/LHighS
2026-04-28Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
2026-04-28Cortisol [Mass/volume] in Serum or Plasma12.6ug/dLMorning sample, drawn before 9 a.m.NormalS
2026-04-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-06-30Hemoglobin [Mass/volume] in Blood11.4g/dL12-15.5 g/dLLowS
2026-06-30Leukocytes [#/volume] in Blood by Automated count4.910*3/uL4-11 10*3/uLNormalS
2026-06-30Neutrophils [#/volume] in Blood by Automated count2.810*3/uL1.5-7.7 10*3/uLNormalS
2026-06-30Platelets [#/volume] in Blood by Automated count22810*3/uL150-400 10*3/uLNormalS
2026-06-30Creatinine [Mass/volume] in Serum or Plasma0.84mg/dL0.59-1.04 mg/dLNormalS
2026-06-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M80mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-06-30Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
2026-06-30Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-06-30Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L8-35 U/LNormalS
2026-06-30Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-06-30Thyrotropin [Units/volume] in Serum or Plasma11.8m[IU]/L0.4-4.5 mIU/LHighS
2026-06-30Thyroxine (T4) free [Mass/volume] in Serum or Plasma0.7ng/dL0.8-1.8 ng/dLLowS
2026-06-30Cortisol [Mass/volume] in Serum or Plasma13.1ug/dLMorning sample, drawn before 9 a.m.NormalS
2026-06-30Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-08-11Thyrotropin [Units/volume] in Serum or Plasma3.6m[IU]/L0.4-4.5 mIU/LNormalS
2026-08-11Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
2026-08-11Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L7-35 U/LNormalS
2026-08-11Glucose [Mass/volume] in Serum or Plasma93mg/dL70-99 mg/dLNormalS
2026-08-11Cholesterol [Mass/volume] in Serum or Plasma204mg/dL<=199 mg/dLHighS
2026-08-11Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation124mg/dL<=129 mg/dLNormalS
2026-08-11Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=50 mg/dLNormalS
2026-08-11Triglyceride [Mass/volume] in Serum or Plasma110mg/dL<=149 mg/dLNormalS
2026-08-11Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-01-05Body height165cmS
2026-01-05Body weight74.6kgS
2026-01-05Body mass index (BMI) [Ratio]27.4kg/m2S
2026-01-05Systolic blood pressure128mm[Hg]S
2026-01-05Diastolic blood pressure80mm[Hg]S
2026-01-05Heart rate78/minS
2026-01-05Respiratory rate16/minS
2026-01-05Body temperature36.7CelS
2026-01-05Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-01-20Body height165cmS
2026-01-20Body weight74.2kgS
2026-01-20Body mass index (BMI) [Ratio]27.3kg/m2S
2026-01-20Systolic blood pressure132mm[Hg]S
2026-01-20Diastolic blood pressure82mm[Hg]S
2026-01-20Heart rate84/minS
2026-01-20Respiratory rate16/minS
2026-01-20Body temperature36.6CelS
2026-01-20Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-02-24Body height165cmS
2026-02-24Body weight72.6kgS
2026-02-24Body mass index (BMI) [Ratio]26.7kg/m2S
2026-02-24Systolic blood pressure124mm[Hg]S
2026-02-24Diastolic blood pressure78mm[Hg]S
2026-02-24Heart rate80/minS
2026-02-24Respiratory rate16/minS
2026-02-24Body temperature36.7CelS
2026-02-24Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-04-28Body height165cmS
2026-04-28Body weight71.8kgS
2026-04-28Body mass index (BMI) [Ratio]26.4kg/m2S
2026-04-28Systolic blood pressure120mm[Hg]S
2026-04-28Diastolic blood pressure76mm[Hg]S
2026-04-28Heart rate82/minS
2026-04-28Respiratory rate16/minS
2026-04-28Body temperature36.6CelS
2026-04-28Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-06-30Body height165cmS
2026-06-30Body weight72.4kgS
2026-06-30Body mass index (BMI) [Ratio]26.6kg/m2S
2026-06-30Systolic blood pressure122mm[Hg]S
2026-06-30Diastolic blood pressure78mm[Hg]S
2026-06-30Heart rate64/minS
2026-06-30Respiratory rate16/minS
2026-06-30Body temperature36.4CelS
2026-06-30Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-08-11Body height165cmS
2026-08-11Body weight73kgS
2026-08-11Body mass index (BMI) [Ratio]26.8kg/m2S
2026-08-11Systolic blood pressure124mm[Hg]S
2026-08-11Diastolic blood pressure78mm[Hg]S
2026-08-11Heart rate70/minS
2026-08-11Respiratory rate16/minS
2026-08-11Body temperature36.6CelS
2026-08-11Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
2026-01-05Three weeks of postmenopausal bleeding in a woman of 60: examination, office endometrial biopsy, transvaginal ultrasound, and gynecologic oncology review bookedfinishedS
2026-01-20Biopsy result: endometrial cancer; staging CT, gynecologic oncology consultation, Lynch syndrome tumor screening, and preparation for surgeryfinishedS
2026-02-24Review three weeks after surgical staging: final pathology and molecular class, genetic counseling, and the first cycle of dostarlimab with carboplatin and paclitaxelfinishedS
2026-04-28Midpoint of combination treatment: blood counts, immune-related adverse event checks, neuropathy, and moodfinishedS
2026-06-30End of combination treatment: response CT, immune-related hypothyroidism, the first maintenance dostarlimab dose, and the survivorship planfinishedS
2026-08-11Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Gynecologic oncology consultation within two weeks to review the endometrial biopsy and ultrasound with her and plan treatment if cancer or atypical hyperplasia is foundcompletedGL-NCCN-UTERINE-2026, GL-ACOG-PMB-2026S
Any bleeding after menopause is evaluated: speculum and bimanual examination, office endometrial biopsy at the first visit, and transvaginal ultrasound within the week, both done rather than relying on endometrial thickness alone; blood count and A1c; results by telephone within days, not at a routine visitcompletedGL-ACOG-PMB-2026, GL-ACOG-CO734-2018, GL-DOLL-2020, GL-CLARKE-2022S
Staging and molecular classification: CT of the chest, abdomen and pelvis; mismatch repair immunohistochemistry and p53 on the biopsy, with MLH1 promoter methylation testing for MLH1 loss and POLE sequencing on the surgical specimen; FIGO 2023 stage with the molecular class recordedcompletedGL-NCCN-UTERINE-2026, GL-FIGO-2023, GL-CMID-2026S
Robotic-assisted total laparoscopic hysterectomy with removal of both tubes and ovaries, pelvic washings, sentinel lymph node mapping with indocyanine green, and removal of the enlarged pelvic and para-aortic nodescompletedGL-NCCN-UTERINE-2026S
Lynch syndrome screening of the tumor for every endometrial cancer, with genetic counseling; germline testing if mismatch repair loss is not explained by MLH1 promoter methylation, and cascade testing offered to blood relatives only if a germline variant is foundcompletedGL-NCCN-UTERINE-2026, GL-ACOG-PB147, GL-CMID-2026S
Dostarlimab 500 mg with carboplatin (AUC 5) and paclitaxel 175 mg/m2 every three weeks for six cycles, then dostarlimab 1000 mg every six weeks for up to three years, for mismatch repair deficient stage IIIC2 disease; hepatitis B, hepatitis C and HIV screening first; three-drug antiemetic prevention; blood counts, kidney function and magnesium before each cycle; TSH, free T4, liver tests, glucose and morning cortisol at baseline and before each cycle; neuropathy checks at each visitcompletedGL-NCCN-UTERINE-2026, GL-RUBY-2023, GL-JEMPERLI-LABEL, GL-ASCO-IRAE-2021, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020, GL-CMID-2026S
Immune-related hypothyroidism: levothyroxine with TSH and free T4 every six weeks, continuing dostarlimabcompletedGL-ASCO-IRAE-2021, GL-JEMPERLI-LABEL, GL-CMID-2026S
Survivorship: examination with a pelvic examination every three months for two years, CT of the chest, abdomen and pelvis every six months for three years, no routine vaginal cytology and no CA-125 (normal at diagnosis), teaching on symptoms of recurrence, lymphedema checks, sexual health, weight, activity, blood pressure, lipid and glucose care, distress screening, and age-appropriate screening for other cancerscompletedGL-SGO-SURV-2026, GL-NCCN-UTERINE-2026, GL-CMID-2026S
Distress and depression screening at each visit, plain explanations, written information, and support she chooses; she decides who receives each notecompletedGL-USPSTF-DEP-2023, GL-NCCN-UTERINE-2026S

Goals

GoalTargetStatusOutcomeProvenance
Endometrial tissue diagnosis and ultrasound within one week, and a gynecologic oncology plan within three weeks of presentation2026-01-20completedBiopsy at the first visit, ultrasound in two days, result in four days, CT in eight, consultation at two weeksS
Surgical staging within four weeks of diagnosis2026-02-24completedMinimally invasive hysterectomy with sentinel node mapping and para-aortic node removal two weeks after the consultationS
Six cycles of dostarlimab with carboplatin and paclitaxel every three weeks without a delay of more than one week2026-06-30completedSix cycles on schedule; CT shows no evidence of diseaseS
Lynch syndrome tumor screening completed and explained before treatment starts2026-02-24completedMLH1 promoter hypermethylation found: acquired, not inherited; genetic counseling doneS
Immune-related adverse events found early: TSH, liver tests, glucose and cortisol checked on schedule2026-06-30completedHypothyroidism found on a scheduled TSH and treated without stopping dostarlimab; one missed baseline cortisol recorded and correctedS
PHQ-9 below 10 throughout treatment, with support she chooses2026-06-30completedPHQ-9 between 4 and 6S

Functional Status

Mental Status